Posts

King’s College London: “From Molecules to Medicines”

News from IFAPP Academy

King’s College London: From Molecules to Medicine

King’s College London, IFAPP Academy’s academic partner, has a strong tradition in pharmaceutical science.

King’s College London has a strong tradition in pharmaceutical science, world-class pharmacology, clinical pharmacology, and therapeutics. This has led to the creation of a number of spin-out companies, including MedPharm and Proximagen Neuroscience plc.

The School of Cancer and Pharmaceutical Science was created to bring together the relevant research groupings across King’s College London.

Molecules to Medicine’s strategy is designed to capture and highlight the broad sweep of research at King’s ranging from pharmacological and chemical studies that can identify novel drug targets and new chemical entities, through formulation and drug development, to clinical trials and the use of medicines by patients. The all-embracing strategy is for researchers to work together towards the discovery of novel medicines and new formulations that can be evaluated in patients in the clinic.

To achieve this goal, and to provide focus, research activities are organized into three related themes: Drug Discovery, Medicines Development, and Medicines Use. Each of these themes includes clusters of research activity, some of which have evolved during the past decade (e.g. drug delivery, chemical biology, pharmaceutical biophysics, pharmacology), and some of which have joined King’s more recently such as enhanced activity in anticancer and anti-infective drug discovery, nanomedicines, substance abuse, health psychology, and clinical pharmacy. Researchers within and across the three themes interact both informally and via joint initiatives to promote cross-disciplinary research. For example, the drug delivery activities of Forbes, Jones, and Daily, working closely with colleagues in pharmacology (Page/Spina) have led to consortium funding and several Ph.D. studentships from the MRC to investigate the safety of nanoparticles in the airways.

This excerpt was originally published on the King’s College website at https://www.kcl.ac.uk/lsm/research/divisions/ips/about/index.aspx

The IFAPP Academy in partnership with King’s College London offers Academic and Professional Certification for students successfully completing the Medical Affairs in Medicines Development course. To learn about the benefits of Certification from the IFAPP Academy, visit us at https://ifappacademy.org/index.php/ifapp-academy-benefits/

Professor Peter Stonier, Co-director of the Medical Affairs Certification program says:

Do you know what PRIME is?

Hot Topics in Medical Affairs


Do you know what PRIME is?

“Paving the way for promising medicines for patients”
European Medicines Agency


Many patients with serious diseases have no or only unsatisfactory therapeutic options and should be able to benefit from scientific advancement and cutting-edge medicines as early as possible.

The European Medicines Agency (EMA) developed PRIME in line with the European Commission’s priorities and the common strategy to 2020 for the European medicines regulatory network. The goal is to foster research on and development of medicines for patients whose diseases cannot be treated or who need better treatment options to help them live healthier lives.

    1.  PRIME is driven by patients’ need.
    2. It focuses on medicines that address an unmet medical need, i.e. offers a major therapeutic advantage over existing treatments or benefits patients with no current treatment options for their disease.
    3. It helps to translate research into the development of medicines while meeting regulatory requirements.
    4. It aims to bring promising treatments to patients earlier, without compromising high evaluation standards and patient safety.


Benefits of PRIME for Medicine Developers

    1. PRIME helps developers of promising new medicines to optimize development plans.
    2. It fosters early dialogue with EMA to facilitate robust data collection and high-quality marketing authorization applications.
    3. It speeds up evaluation so that medicines can reach patients earlier.
    4. It encourages developers to focus resources on medicines likely to make a real difference to patients’ lives.

This article was originally published on the EMA website. To view the full publication please visit this direct link: http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2016/03/WC500202670.pdf

Want to learn more about the European Medicines Agency and its initiatives?

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy provides online Continuing Professional Development for Medical Affairs Professionals.

The IFAPP Academy is a non-profit organization whose mission is to promote, develop, and implement educational activities that support Pharmaceutical Medicine by enhancing the knowledge, expertise, and skills of pharmaceutical physicians and medicines development scientists worldwide. Partnered with King’s College London, the Academy offers Professional Certification for students successfully completing the course. Click here to learn more about the benefits of Professional Certification from the IFAPP Academy.


IFAPP Academy 2018 Steering Committee Meeting

News from IFAPP Academy

IFAPP Academy 2018 Steering Committee Meeting


The first IFAPP Academy Steering Committee meeting of 2018 was held in Barcelona, Spain at the end of January.  The 3-day agenda allowed committee members to discuss a wide range of topics and initiatives for the upcoming academic year and enjoy the beautiful country and delicious food.

A review of the previous academic year was conducted with a lot of focus directed on the lessons learned and the experience of the participating sponsors. This helped to provide great direction in developing improvements for the years to come.

An overview of the new student cohort showed that the IFAPP Academy now has students in 48 different countries.

 

The 2018 students are also employed by a larger array of pharmaceutical companies compared to the previous year.

The IFAPP Academy Steering Committee is excited to be expanding its outreach and working on the new initiatives to provide students with the best in Medical Affairs in Medicines Development education.


Importance of Big Data for Medical Affairs Professionals

Hot Topics in Medical Affairs


The Importance of Big Data for Medical Affairs Professionals

How harnessing the power of big data can give Medical Affairs Professionals the strategic edge.



The most competitive companies in pharma must inundate themselves with data to navigate and excel in an ever increasingly complex environment. But, according to Bain & Company, companies have difficulty explaining the science and data to stakeholders in an effective and meaningful way.1 Just imagine a chemical engineer trying to explain chocolate milk to a 3-year-old. According to Bain research, this shortfall is one attributing factor to the 50% of launches that fail to meet company expectations.

So how does a company manage this problem without losing sight of their main goal, the resulting product? This is where a Medical Affairs Professional comes to the rescue. The ability for a Medical Affairs Professional to collect, analyze, interpret and present data can help ensure the success of a company.

Why is big data so important? Drug development has become more focused on narrower and more personal indications resulting in a more involved treatment. This trend, along with rising costs, and a greater multiplex for physicians to navigate has left a gap that leading companies are filling with medical affairs teams to help them translate their data in a way that physicians, payers, and providers can understand. While the company can focus on their products, they can leave the Medical Affairs Professionals to sort and distribute their big data in a valuable, effective, and consumable way.

Want to learn how to leverage company big data throughout the drug development process?

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy provides online Continuing Professional Development for Medical Affairs Professionals.

The IFAPP Academy is a non-profit organization whose mission is to promote, develop, and implement educational activities that support Pharmaceutical Medicine by enhancing the knowledge, expertise, and skills of pharmaceutical physicians and medicines development scientists worldwide. Partnered with King’s College London, the Academy offers Professional Certification for students successfully completing the course. Click here to learn more about the benefits of Professional Certification from the IFAPP Academy.

To read more about big data in the world of Medical Affairs please check out this great article from Bain & Company: Reinventing the Role of Medical Affairs.

 

References:

  1. Plantevin L, Schlegel C, Gordian M. Reinventing the Role of Medical Affairs. Bain & Company. http://www.bain.com/publications/articles/reinventing-the-role-of-medical-affairs.aspx. Published March 15, 2017. Accessed January 11, 2018.